Intercept Eyes EU NASH Market

Analysts believe that pan-EU authorization for Intercept Pharmaceuticals’ obeticholic acid for advanced fibrosis due to nonalcoholic steatohepatitis may come in the first quarter of 2021.

ealthcare and pharmacy concept - different pills and capsules of drugs in shape of liver
Several companies are in the race to market a drug for NASH in the industrialized world

Intercept Pharmaceuticals, which recently submitted a marketing application to the European Medicines Agency for obeticholic acid, believes the product has the potential to become an essential treatment for people living with advanced fibrosis due to nonalcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease.

Intercept is among several companies in the race to market a drug for NASH in the industrialized world; the company...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet